ADVERTISEMENT

Stay up to date every week with the european biotechnology newsletter.

✕

Email(Required)

This field is hidden when viewing the form

EBcom NL

confirm list

This field is hidden when viewing the form

Consent

I agree to the privacy policy.

Comments

This field is for validation purposes and should be left unchanged.

Stay up to date every week with the european biotechnology newsletter.

Log in here to read the desired article.

Email(Required)

This field is hidden when viewing the form

EBcom NL

confirm list

This field is hidden when viewing the form

Consent

I agree to the privacy policy.

Comments

This field is for validation purposes and should be left unchanged.

go to the article

go back to the homepage

BIOCOM CARD
Newsletter
Advertising
Job Market
Shop

Latest news
Background
Opinion
The Mag
- Issues
- Special
- Subscribe
Euro Biotech Guide
Market Place
Associations
Service
Events
Search
Menu Menu

ADVERTISEMENT

SPONSORED PUBLICATIONS

Humanized NSG and NSG-SGM3 mice as a new p...

Page 19 of 19«‹17 1819

LATEST NEWS

SpliceBio lauches Phase I/II study on dual-AAV-base...

Regulatory sandbox will speed up safety assessment...

asobe stock photos - catalin

Roche inks US$1.65bn obesity deal with Zealand Phar...

ADVERTISEMENT

MAGAZINE

1 / 4

Since the first antibody drug was approved back in 1986, monoclonal antibodies have emerged as the dominant class in the global US$417bn market for biologics. At the end of 2023, sales stood at more … mehr ➔

2 / 4

The first half of 2024 is history, and experts are divided on whether the financing nadir has been reached or even passed. There are very different figures for different types of treatments under … mehr ➔

3 / 4

The Three R (Replacement, Reduction and Refinement) principles developed over 60 years ago provide a framework for more humane lab animal testing and, more importantly, less of it. A range of in-vitro … mehr ➔

4 / 4

Radiopharmaceuticals have turned into a hot commodity when it comes to M&A financing and deals. Targeted therapies that employ high-energy attachments linked to antibodies, small molecules or … mehr ➔

SPONSORED PUBLICATION

1 / 2

Sino Biological

Sino Biological

Gilead’s Capsid Revolution Meets Our Capsid Solutions: Sino Biological – Engineering the Tools to Outsmart HIV

High-Quality HIV Antigens for Cutting-Edge Solutions mehr ➔

2 / 2

New England Biolabs

The Bridge to your success

Customized Enzymes and Reagents from New England Biolabs mehr ➔

newsletter_link

© BIOCOM Interrelations GmbH

LinkedIn
Instagram

Contact
Imprint
Privacy policy